Abortion Drug Makers Prioritize Profits Over Women's Safety
Source: Jordan Boyd. "Abortion Drug Makers Admit They Care About Money, Not Women." May 6, 2026. thefederalist.com
The Gist
The author argues that abortion pill companies care more about making money than keeping women safe. They point to a court case where the drug company openly said their profits should matter more than safety concerns, and cite statistics showing the pills cause serious health problems.
Conclusion
Abortion drug manufacturers like Danco Laboratories prioritize their financial interests over the safety and wellbeing of women who use their products
Premises
- Danco Laboratories explicitly argued that its 'substantial financial interest' in selling abortion drugs should outweigh Louisiana's safety concerns
- The 5th Circuit Court found that Danco's financial concerns 'pale beside Louisiana's sovereign interest in protecting the unborn and the public's interest in not exposing women to unsafe medical procedures'
- Chemical abortion causes severe side effects including bleeding, breathing trouble, hemorrhage, and infection, with over 10% of women experiencing serious adverse events
- Mail-order abortion pills allow women to take dangerous drugs without proper medical supervision or evaluation
- Louisiana demonstrated significant taxpayer costs from treating women who needed emergency care after unsupervised mifepristone use
- Danco has no direct relationship with patients and little ability to track adverse events from their drugs
Assumptions
- Companies should prioritize public safety over profits when manufacturing medical products
- Court statements accurately reflect companies' true motivations and priorities
- Medical supervision is necessary for safe use of abortion medications
- The reported adverse event statistics are accurate and representative